Monitoring Agency Report for the Quarter ended June 30, 2026.

3rd August, 2026 To, To, The Secretary, The Secretary, Bombay Stock Exchange Ltd (BSE) National Stock Exchange (NSE), Phiroze Jheejheebhoy Towers, Exchange Plaza, Dalal Street, 5th Floor Plot No.C/1, 'G' Block Mumbai - 400 001. Bandra - Kurla Complex Scrip Code - 543308 Mumbai - 400 051. ISIN: INE967H01025 Symbol - KIMS Dear Sir/ Madam Sub: Monitoring Agency Report for the quarter ended June 30, 2026 Ref: Funds raised through Qualified Institutional Placement. Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 162A(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Monitoring Agency Report for the quarter ended on 30th June, 2026, issued by CARE Ratings Limited, duly reviewed by the Audit Committee of the Company is enclosed herewith. Kindly take the above on your records. Thanking You, Yours truly For Krishna Institute of Medical Sciences Limited Nagajayanthi J. R Company Secretary and Compliance Officer No. CARE/HRO/GEN/2026-27/1015 The Board of Directors Shri B. Bhaskara Rao Managing Director Krishna Institute of Medical Sciences Limited D.No. 1-8-31/1, Minister Road, Secunderabad Telangana - 500003 August 03, 2026 Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 in relation to the QIP issue of Krishna Institute of Medical Sciences Limited (“the Company” or “KIMS”) We write in our capacity of Monitoring Agency for the QIP for the amount aggregating to ₹1,500 crore of the Company and refer to our duties cast under Regulation 173A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018, amended from time to time. In this connection, we are enclosing the Monitoring Agency Report for the quarter ended June 30, 2026 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated June 16, 2026. Request you to kindly take the same on records. Thanking you, Yours faithfully, Pritesh Rathi Associate Director Pritesh.Rathi@careedge.in CARE Ratings Limited 401, Ashoka Scintilla, 3-6-520, Himayat Nagar, Corporate Office :4th Floor, Godrej Coliseum, Hyderabad - 500 029 Somaiya Hospital Road, Off Eastern Express Phone: +91-40-4010 2030 Highway, Sion (E), Mumbai - 400 022 Phone: +91-22-6754 3456 • www.careedge.in Page 1 of 11 Report of the Monitoring Agency Name of the issuer: Krishna Institute of Medical Sciences Ltd For quarter ended: June 30, 2026 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: Nil (b) Range of Deviation: Nil Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The Monitoring Agency (MA) does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Pritesh Rathi Designation of Authorized person/Signing Authority: Associate Director CARE Ratings Limited 401, Ashoka Scintilla, 3-6-520, Himayat Nagar, Corporate Office :4th Floor, Godrej Coliseum, Hyderabad - 500 029 Somaiya Hospital Road, Off Eastern Express Phone: +91-40-4010 2030 Highway, Sion (E), Mumbai - 400 022 Phone: +91-22-6754 3456 • www.careedge.in Page 2 of 11 1) Issuer Details: Name of the issuer : Krishna Institute of Medical Sciences Limited Name of the promoter : Mr. Bhaskara Rao Bollineni Industry/sector to which it belongs : Healthcare 2) Issue Details Issue Period : June 16, 2026 to June 19, 2026 Type of issue (public/rights) : QIP Type of specified securities : Shares IPO Grading, if any : NA Issue size (in crore) : ₹1,500 crore 3) Details of the arrangement made to ensure the monitoring of issue proceeds: CARE Ratings Limited 401, Ashoka Scintilla, 3-6-520, Himayat Nagar, Corporate Office :4th Floor, Godrej Coliseum, Hyderabad - 500 029 Somaiya Hospital Road, Off Eastern Express Phone: +91-40-4010 2030 Highway, Sion (E), Mumbai - 400 022 Phone: +91-22-6754 3456 • www.careedge.in Page 3 of 11 Source of information / certifications Comments of Comments of the Particulars Reply considered by Monitoring Agency for the Board of Monitoring Agency preparation of report Directors Chartered Accountant certificate*, As per the placement document, the net Whether all utilization is as per the disclosures in the Offer utilization certificate from the proceeds of ₹1,476.45 crore are to be No comments Document? management^, Bank statements and Loan utilised by FY27. During Q1FY27, the received account statements. company has utilised ₹1,084 crores. No material Whether shareholder approval has been obtained in case of deviation. No comments material deviations# from expenditures disclosed in the Offer As confirmed by the issuer’s management Nil Hence, not received Document? applicable Whether the means of finance for the disclosed objects of the No comments No As confirmed by the issuer’s management Nil issue have changed? received Is there any major deviation observed over the earlier NA as this is The issue closed on June 19, 2026, this is No comments monitoring agency reports? the first report the first MA report received Whether all Government/statutory approvals related to the No comments Not applicable Confirmation from management Nil object(s) have been obtained? received Whether all arrangements pertaining to technical No comments Not applicable Confirmation from management Nil assistance/collaboration are in operation? received Are there any favorable/unfavorable events affecting the No major No comments Confirmation from management Nil viability of these object(s)? events received For utilisation towards general corporate purposes (GCP), the proceeds from the QIP were transferred into the company’s Is there any other relevant information that may materially and subsidiary companies’ current No comments No Confirmation from management affect the decision making of the investors? accounts. As these accounts are also used received for routine business transactions, the monitored proceeds were commingled with regular business funds. *Chartered Accountant certificate from B. Naga Bh [Showing first 8,000 characters — download PDF for full document]